|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
In this era spread of multidrug resistance is a global problem. P. aeruginosa is one of the most common nosocomial pathogen causing wide range of opportunistic infections. Rapid emergence of varying degrees of innate & acquired resistance mechanisms has put forward a major challenge in their detection as well as treatment options. We did a prospective study, from January 2016 to December 2016, in Department of Microbiology at Government Medical College, Aurangabad. Out of 3,340 culture positive samples, 676 (20.23%) were identified as P. aeruginosa by standard bacteriological identification methods, from various specimens. Antimicrobial sensitivity testing was done by Modified Kirby-Bauer disc diffusion method as per CLSI guidelines 2016. Results showed maximum antibiotic resistance to Nalidixic acid (100%), Ampicillin (83.3), Ceftriaxone (72.8%), Nitrofurantoin (72%), Cefepime (62.9%), Norfloxacin (65.2%), Cefotaxime (57.6%), Ceftazidime (56.1%) against Colistin (94.9%), Amikacin (93.9%), Piperacillin/Tazobactam (94.3%), Imipenem (82.2%), Cefoxitin (67.6%) Ceftazidime/Clavulanic acid (57.9%) which were identified as the most effective antibiotics. Prevalence of ESBL, AmpC and MBL producers was found to be 21.74%, 10.62% and 9.31% respectively. Conclusion: Emerging multi drug resistant P. aeruginosa needs inevitable screening and confirmation for β - lactamases production so that proper treatment can be initiated with appropriate antibiotics for commendable outcome, further their spread can be prevented by applying infection control policy and judicious use of antibiotics in the hospital.